2018年(英文)

原著

  1. Arima N, Kanda J, Tanaka J, Yabe T, Morishima Y, Kim SW, Najima Y, Ozawa Y, Eto T, Kanamori H, Mori T, Kobayashi N, Kondo T, Nakamae H, Uchida N, Inoue M, Fukuda T, Ichinohe T, Atsuta Y, Kanda Y:

    Homozygous HLA-C1 is associated with reduced risk of relapse after HLA-matched transplantation in patients with myeloid leukemia.
    Biol Blood Marrow Transplant 24(4): 717-725, 2018.

  2. Fujimaki K, Hattori Y, Nakajima H:

    10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.
    Int J Hematol 107: 709-711,2018.

  3. Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T:

    Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
    Ann Hematol. 97(11): 2081-2088, 2018.

  4. Fujiwara S, Fujishima N, Kanamori H, Ito M, Sugimoto T, Saito S, Sakaguchi T, Nagai K, Masuoka H, Nagai K, Morita A, Kino S, Tanaka A, Hasegawa Y, Yokohama A, Fujino K, Makino S, Matsumoto M, Takeshita A, Muroi K:

    Released washed platelet concentrates are effective and safe in patients with a history of transfusion reactions.
    Transfus Apher Sci 57(6): 746-751, 2018.

  5. Goto T, Tanaka T, Sawa M, Ueda Y, Ago H, Chiba S, Kanamori H, Nishikawa A, Nougawa M, Ohashi K, Okumura H, Tanimoto M, Fukuda T, Kawashima N, Kato T, Okada K, Nagafuji K, Okamoto SI, Atsuta Y, Hino M, Tanaka J, Miyamura K:

    Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan.
    Int J Hematol 107(2): 211-221, 2018.

  6. Harada K, Doki N, Aoki J, Mori J, Machida S, Masuko M, Uchida N, Najima Y, Fukuda T, Kanamori H, Ogawa H, Ota S, Ogawa K, Takahashi S, Kasai M, Maeda A, Nagafuji K, Kawakita T, Ichinohe T, Atsuta Y:

    Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15).
    Haematologica, 103: e69-e72, 2018.

  7. Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K:

    Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.
    Ann Hematol. 97(1): 73-81, 2018.

  8. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG:

    Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
    Leuk Res 66(3): 20-27, 2018.

  9. Hatta Y, Mizuta S, Matuso K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T. Final analysis of the JALSG Ph+ALL202 study:

    tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
    Ann Hematol 97(9): 1532-1545, 2018.

  10. Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T:

    Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.
    Med Oncol. 35(11): 142, 2018.

  11. Ishii Y, Fujisawa S, Ando T, Suzuki T, Ishiyama Y, Kishimoto K, Hattori Y, Nakajima Y, Miyazaki T, Takasaki H, Matsumoto K, Koharazawa H, Taguchi J, Fujimaki K, Sakai R, Nakajima H: Primary uterine lymphoma:

    The Yokohama Cooperative Study Group for Hematology (YACHT) study.
    Asia Pac J Clin Oncol, 14(5): e455-e459, 2018.

  12. Ishii Y, Fujisawa S, Nigauri C, Ando T, Suzuki T, Ogusa E, Miyashita K, Motohashi K, Nakajima H:

    Peripheral Blood Monocyte Count is a Predictor of Successful Peripheral Blood Stem Cell Harvest After Chemo-Mobilization in Patients with Malignant Lymphoma.
    Indian J Hematol Blood Transfus, 34(2): 347-349, 2018.

  13. Itonaga H, Aoki K, Aoki J, Ishikawa T, Ishiyama K, Uchida N, Sakura T, Ohashi K, Kurokawa M, Ozawa Y, Matsuoka KI, Nakamura Y, Kimura F, Iwato K, Nawa Y, Hirokawa M, Kato K, Ichinohe T, Atsuta Y, Miyazaki Y: Prognostic Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Adults with Chronic Myelomonocytic Leukemia:

    a Nationwide Retrospective Analysis in Japan.
    Biol Blood Marrow Transplant, 24: 840-848, 2018.

  14. Iwasaki H, Yamazaki H, Takasaki H, Suganuma N, Nakayama H, Toda S, Masudo K.: Lenvatinib as a novel treatment for anaplastic thyroid cancer:

    A retrospective study.
    Oncol Lett, 16(6): 7271-7277, 2018.

  15. Kawamoto K, Miyoshi H, Suzuki T, Kozai Y, Kato K, Miyahara M, Yujiri T, Choi I, Fujimaki K, Muta T, Kume M, Moriguchi S, Tamura S, Kato T, Tagawa H, Makiyama J, Kanisawa Y, Sasaki Y, Kurita D, Yamada K, Shimono J, Sone H, Takizawa J, Seto M, Kimura H, Ohshima K. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder:

    adult patients with chronic active Epstein-Barr virus infection-like features.
    Haematologica, 103: 1018-1028, 2018.

  16. Kawamura K, Nakasone H, Kurosawa S, Yoshimura K, Misaki Y, Gomyo A, Hayakawa J, Tamaki M, Akahoshi Y, Kusuda M, Kameda K, Wada H, Ishihara Y, Sato M, Terasako-Saito K, Kikuchi M, Kimura SI, Tanihara A, Kako S, Kanamori H, Mori T, Takahashi S, Taniguchi S, Atsuta Y, Kanda Y:

    Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success.
    Biol Blood Marrow Transplant, 24(7): 1521-1526, 2018.

  17. Konuma T, Mizuno S, Kondo T, Yamaguchi H, Fukuda T, Uchida N, Najima Y, Kanamori H, Ota S, Nakamae H, Nakamae M, Mizuno I, Sugita J, Onishi Y, Yokota A, Takahashi S, Kanda Y, Ichinohe T, Atsuta Y, Yano S:

    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT).
    Ann Hematol, 97(11): 2173-2183, 2018.

  18. Kunimoto H, Meydan C, Nazir A, Whitfield J, Shank K, Rapaport F, Maher R, Pronier E, Meyer SC, Garrett-Bakelman FE, Tallman M, Melnick A, Levine RL, Shih AH:

    Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity.
    Cancer Cell, 33:44-59, 2018.

  19. Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H:

    Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.
    Int J Hematol, 107(2):201-210, 2018.

  20. Matsumoto K, Fujisawa S, Ando T, Koyama M, Koyama S, Ishii Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Nakajima H: Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients:

    A Single-Center Retrospective Study.
    Turk J Haematol, 35(3): 181-184, 2018.

  21. Miyaoka M, Kikuti Y, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N:

    Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Mod Pathol, 31(2): 313-326, 2018.

  22. Motohashi K, Fujisawa S, Doki N, Kobayashi T, Mori T, Usuki K, Tanaka M, Fujiwara S, Kako S, Aoyama Y, Onoda M, Yano S, Gotoh M, Kanamori H, Takahashi S, Okamoto S:

    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma, 59(6): 1332-1337, 2018.

  23. Nakajima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K:

    Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
    Leuk Res, 66: 66-72, 2018.

  24. Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y,Komatsu N, Kawaguchi T.

    Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Med Onco, 35(7): 99, 2018.

  25. Ogata M, Takano K, Moriuchi Y, Kondo T, Ueki T, Nakano N, Mori T, Uoshima N, Nagafuji K, Yamasaki S, Shibasaki Y, Sakai R, Kato K, Choi I, Jo Y, Eto T, Kako S, Oshima K, Fukuda T: Effects of Prophylactic Foscarnet on Human Herpesvirus-6 Reactivation and Encephalitis in Cord Blood Transplant Recipients:

    A Prospective Multicenter Trial with an Historical Control Group.
    Biol Blood Marrow Transplant, 24(6): 1264-1273, 2018.

  26. Ogawa H, Ikegame K, Daimon T, Uchida N, Fukuda T, Kakihana K, Eto T, Ozawa Y, Kanamori H, Hidaka M, Iwato K, Ichinohe T, Takanashi M, Atsuta Y, Kanda Y:

    Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR.
    Bone Marrow Transplant, 53(4): 478-482, 2018.

  27. Saito H, Ito M, Kato S, Kodera Y, Okamoto S, Taniguchi S, Takanashi M, Kanamori H, Masaoka T, Takaku F on behalf of JMDP; The Japan Marrow Donor Program:

    25 years of experience in achieving 20,000 bone marrow transplantations: organization structure, activity, and financial basis.
    Bone Marrow Transplant, 53(5): 609-616, 2018.

  28. Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T:

    High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
    Leukemia, 32: 626-632, 2018.

  29. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

    Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.
    Leuk Lymphoma. 59(5): 1105-1112, 2018.

  30. Tachibana T, Kanda J, Machida S, Saito T, Tanaka M, Najima Y, Koyama S, Miyazaki T, Yamamoto E, Takeuchi M, Morita S, Kanda Y, Kanamori H, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT):

    Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302).
    Int J Hematol, 107(5): 578-585, 2018.

  31. Tachibana T, Ando T, Tanaka M, Ito S, Miyazaki T, Ishii Y, Ogusa E, Koharazawa H, Takahashi H, Motohashi K, Aoki J, Nakajima Y, Matsumoto K, Hagihara M, Hashimoto C, Taguchi J, Fujimaki K, Fujita H, Fujisawa S, Kanamori H, Nakajima H:

    Clinical Significance of Serum Ferritin at Diagnosis in Patients With Acute Myeloid Leukemia: A YACHT Multicenter Retrospective Study.
    Clin Lymphoma Myeloma Leuk, 18(6): 415-421, 2018.

  32. Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T:

    Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
    Med Oncol, 35(3): 38, 2018.

  33. Tomita N, Yokoyama M, Yamamoto W, Watanabe R, Shimazu Y, Masaki Y, Tsunoda S, Hashimoto C, Murayama K, Yano T, Okamoto R, Kikuchi A, Tamura K, Sato K, Sunami K, Shibayama H, Takimoto R, Ohshima R, Takahashi H, Moriuchi Y, Kinoshita T, Yamamoto M, Numata A, Nakajima H, Miura I, Takeuchi K:

    The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
    Leuk Lymphoma, 59(1): 97-104, 2018.

  34. Yamamoto M, Ushio R, Watanabe H, Tachibana T, Tanaka M, Yokose T, Tsukiji J, Nakajima H, Kaneko T.

    Detection of Mycobacterium tuberculosis-derived DNA in circulating cell-free DNA from a patient with disseminated infection using digital PCR.
    Int J Infect Dis 66: 80-82, 2018.

  35. Yanada M, Mori J, Aoki J, Harada K, Mizuno S, Uchida N, Kurosawa S, Toya T, Kanamori H, Ozawa Y, Ogawa H, Henzan H, Iwato K, Sakura T, Ota S, Fukuda T, Ichinohe T, Atsuta Y, Yano S:

    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma, 59: 601-609, 2018.

ページトップへ